Scholar Rock Advances SMA Treatment Amid Financial Losses
Scholar Rock Holding ( (SRRK) ) has released its Q3 earnings. Here is a breakdown of the information Scholar Rock Holding presented to its investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Scholar Rock is a biopharmaceutical company focused on developing treatments for spinal muscular atrophy (SMA) and other rare neuromuscular diseases, leveraging its expertise in myostatin biology to advance musculoskeletal health. In its latest earnings report, Scholar Rock highlighted its progress in the development of apitegromab, a muscle-targeted treatment for SMA, following a constructive meeting with the FDA. The company anticipates resubmitting its biologics license application and launching apitegromab in the U.S. in 2026, with European regulatory review ongoing. Financially, Scholar Rock reported a net loss of $102.2 million for the third quarter of 2025, with increased expenses attributed to investments in manufacturing and launch readiness for apitegromab. Despite the losses, the company maintains a strong cash position of $369.6 million, expected to fund operations into 2027. Looking ahead, Scholar Rock remains committed to advancing its strategic programs and establishing itself as a leader in muscle-targeted therapeutics, with plans to initiate clinical development in a second neuromuscular disorder by the end of 2025.
